{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:15:53Z","timestamp":1786968953310,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Statins present many beneficial effects in chronic liver disease, but concerns about safety exist. We evaluated the hepatic effects of a nitric oxide-releasing atorvastatin (NCX 6560) compared to conventional statins. Simvastatin, atorvastatin and NCX 6560 were evaluated in four-week bile duct-ligated rats (BDL) simulating decompensated cirrhosis and in thirteen-week carbon tetrachloride (CCl\n                    <jats:sub>4<\/jats:sub>\n                    ) intoxicated rats, a model of early cirrhosis. In the BDL model, simvastatin treated rats showed high mortality and the remaining animals presented muscular and hepatic toxicity. At equivalent doses, NCX 6560 eliminated hepatic toxicity and reduced muscular toxicity (60\u201374%) caused by atorvastatin in the more advanced BDL model; toxicity was minimal in the CCl\n                    <jats:sub>4<\/jats:sub>\n                    model. Atorvastatin and NCX 6560 similarly reduced portal pressure without changing systemic hemodynamics in both models. Atorvastatin and NCX 6560 caused a mild decrease in liver fibrosis and inflammation and a significant increase in intrahepatic cyclic guanosine monophosphate. NCX 6560 induced a higher intrahepatic vasoprotective profile (activated endothelial nitric oxide synthase and decreased platelet\/endothelial cell adhesion molecule-1), especially in the CCl\n                    <jats:sub>4<\/jats:sub>\n                    model, suggesting a higher benefit in early cirrhosis. In conclusion, NCX 6560 improves the liver profile and portal hypertension of cirrhotic rats similarly to conventional statins, but with a much better safety profile.\n                  <\/jats:p>","DOI":"10.1038\/srep40461","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T05:06:23Z","timestamp":1484283983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats"],"prefix":"10.1038","volume":"7","author":[{"given":"Sarai","family":"Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imma","family":"Raurell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Torres-Arauz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Garc\u00eda-Lezana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Genesc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Martell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"key":"BFsrep40461_CR1","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/hep.23478","volume":"51","author":"G Garcia-Tsao","year":"2010","unstructured":"Garcia-Tsao, G. et al. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 51, 1445\u20131449 (2010).","journal-title":"Hepatology"},{"key":"BFsrep40461_CR2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4254\/wjh.v2.i6.208","volume":"2","author":"M Martell","year":"2010","unstructured":"Martell, M. et al. Physiopathology of splanchnic vasodilation in portal hypertension. World. J. Hepatol. 2, 208\u2013220 (2010).","journal-title":"World. J. Hepatol."},{"key":"BFsrep40461_CR3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2012.03.007","volume":"57","author":"JC Garcia-Pagan","year":"2012","unstructured":"Garcia-Pagan, J. C. et al. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J. Hepatol. 57, 458\u2013461 (2012).","journal-title":"J. Hepatol."},{"key":"BFsrep40461_CR4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jhep.2006.11.008","volume":"46","author":"A Rodriguez-Vilarrupla","year":"2007","unstructured":"Rodriguez-Vilarrupla, A. et al. Potential role of antioxidants in the treatment of portal hypertension. J. Hepatol. 46, 193\u2013197 (2007).","journal-title":"J. Hepatol."},{"key":"BFsrep40461_CR5","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.jhep.2008.01.021","volume":"48","author":"J Bosch","year":"2008","unstructured":"Bosch, J. et al. The management of portal hypertension: Rational basis, available treatments and future options. J. Hepatol. 48, S68\u2013S92 (2008).","journal-title":"J. Hepatol."},{"key":"BFsrep40461_CR6","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1053\/jhep.2001.27545","volume":"34","author":"TD Boyer","year":"2001","unstructured":"Boyer, T. D. Pharmacologic treatment of portal hypertension: past, present, and future. Hepatology 34, 834\u2013839 (2001).","journal-title":"Hepatology"},{"key":"BFsrep40461_CR7","first-page":"800","volume":"17","author":"JM Salmeron","year":"1993","unstructured":"Salmeron, J. M. et al. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology 17, 800\u2013806 (1993).","journal-title":"Hepatology"},{"key":"BFsrep40461_CR8","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/01.mcg.0000155513.17715.f7","volume":"39","author":"M Hernandez-Guerra","year":"2005","unstructured":"Hernandez-Guerra, M. et al. Increased hepatic resistance - A new target in the pharmacologic therapy of portal hypertension. J. Clin. Gastroenterol. 39, S131\u2013S137 (2005).","journal-title":"J. Clin. Gastroenterol."},{"key":"BFsrep40461_CR9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","volume":"126","author":"C Zafra","year":"2004","unstructured":"Zafra, C. et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 126, 749\u2013755 (2004).","journal-title":"Gastroenterology"},{"key":"BFsrep40461_CR10","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","volume":"46","author":"JG Abraldes","year":"2007","unstructured":"Abraldes, J. G. et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J. Hepatol. 46, 1040\u20131046 (2007).","journal-title":"J. Hepatol."},{"key":"BFsrep40461_CR11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","volume":"46","author":"J Trebicka","year":"2007","unstructured":"Trebicka, J. et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46, 242\u2013253 (2007).","journal-title":"Hepatology"},{"key":"BFsrep40461_CR12","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","volume":"136","author":"JG Abraldes","year":"2009","unstructured":"Abraldes, J. G. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136, 1651\u20131658 (2009).","journal-title":"Gastroenterology"},{"key":"BFsrep40461_CR13","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","volume":"126","author":"N Chalasani","year":"2004","unstructured":"Chalasani, N. et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 126, 1287\u20131292 (2004).","journal-title":"Gastroenterology"},{"key":"BFsrep40461_CR14","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.14309\/00000434-200410001-00211","volume":"99","author":"R Vuppalanchi","year":"2004","unstructured":"Vuppalanchi, R. et al. Patients with elevated liver enzymes are not at higher risk for hepatotoxicity from lovastatin than those with normal liver enzymes. Am. J. Gastroenterol. 99, S69\u2013S70 (2004).","journal-title":"Am. J. Gastroenterol."},{"key":"BFsrep40461_CR15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2011.08.016","volume":"56","author":"T Bader","year":"2012","unstructured":"Bader, T. Yes! Statins can be given to liver patients. J. Hepatol. 56, 305\u2013307 (2012).","journal-title":"J. Hepatol."},{"key":"BFsrep40461_CR16","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.dld.2006.04.013","volume":"38","author":"AT Clarke","year":"2006","unstructured":"Clarke, A. T. & Mills, P. R. Atorvastatin associated liver disease. Dig. Liver Dis. 38, 772\u2013777 (2006).","journal-title":"Dig. Liver Dis."},{"key":"BFsrep40461_CR17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0029-1240010","volume":"29","author":"MW Russo","year":"2009","unstructured":"Russo, M. W. et al. Drug-induced liver injury associated with statins. Sem. Liver Dis. 29, 412\u2013422 (2009).","journal-title":"Sem. Liver Dis"},{"key":"BFsrep40461_CR18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","volume":"56","author":"E Bjornsson","year":"2012","unstructured":"Bjornsson, E. et al. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J. Hepatol. 56, 374\u2013380 (2012).","journal-title":"J. Hepatol."},{"key":"BFsrep40461_CR19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1089\/ars.2013.5430","volume":"20","author":"M Margaritis","year":"2014","unstructured":"Margaritis, M. et al. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid. Redox Signal 20, 1198\u20131215 (2014).","journal-title":"Antioxid. Redox Signal"},{"key":"BFsrep40461_CR20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","volume":"5","author":"C Stancu","year":"2001","unstructured":"Stancu, C. & Sima, A. Statins: mechanism of action and effects. J. Cell. Mol. Med. 5, 378\u2013387 (2001).","journal-title":"J. Cell. Mol. Med."},{"key":"BFsrep40461_CR21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1089\/ars.2013.5524","volume":"20","author":"N Sawada","year":"2014","unstructured":"Sawada, N. & Liao, J. K. Rho\/Rho-Associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid. Redox Signal 20, 1251\u20131267 (2014).","journal-title":"Antioxid. Redox Signal"},{"key":"BFsrep40461_CR22","doi-asserted-by":"crossref","first-page":"G147","DOI":"10.1152\/ajpgi.00462.2007","volume":"296","author":"M Moreno","year":"2009","unstructured":"Moreno, M. et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. A. J. Physiol.-Gastrointest. Liver Physiol. 296, G147\u2013G156 (2009).","journal-title":"A. J. Physiol.-Gastrointest. Liver Physiol"},{"key":"BFsrep40461_CR23","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","volume":"53","author":"J Trebicka","year":"2010","unstructured":"Trebicka, J. et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J. Hepatol. 53, 702\u2013712 (2010).","journal-title":"J. Hepatol."},{"key":"BFsrep40461_CR24","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/labinvest.2012.106","volume":"92","author":"S Klein","year":"2012","unstructured":"Klein, S. et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab. Invest. 92, 1440\u20131450 (2012).","journal-title":"Lab. Invest."},{"key":"BFsrep40461_CR25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/gut.2010.220913","volume":"60","author":"J Gracia-Sancho","year":"2011","unstructured":"Gracia-Sancho, J. et al. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut 60, 517\u2013524 (2011).","journal-title":"Gut"},{"key":"BFsrep40461_CR26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","volume":"58","author":"G Marrone","year":"2013","unstructured":"Marrone, G. et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J. Hepatol. 58, 98\u2013103 (2013).","journal-title":"J. Hepatol."},{"key":"BFsrep40461_CR27","doi-asserted-by":"crossref","unstructured":"Abraldes, J. G. et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 150, 1160-1170.e3, doi: 10.1053\/j.gastro.2016.01.004 (2016).","DOI":"10.1053\/j.gastro.2016.01.004"},{"key":"BFsrep40461_CR28","doi-asserted-by":"publisher","first-page":"14573","DOI":"10.1038\/srep14573","volume":"5","author":"FE Uschner","year":"2015","unstructured":"Uschner, F. E. et al. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep. 5, 14573, doi: 10.1038\/srep14573 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep40461_CR29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2007.05.014","volume":"570","author":"S Momi","year":"2007","unstructured":"Momi, S. et al. NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur. J. Pharmacol. 570, 115\u2013124 (2007).","journal-title":"Eur. J. Pharmacol."},{"key":"BFsrep40461_CR30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/cvr\/cvs100","volume":"94","author":"S Momi","year":"2012","unstructured":"Momi, S. et al. Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Cardiovasc. Res. 94, 428\u2013438 (2012).","journal-title":"Cardiovasc. Res."},{"key":"BFsrep40461_CR31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/mus.23465","volume":"47","author":"G D\u2019Antona","year":"2013","unstructured":"D\u2019Antona, G. et al. Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice. Muscle Nerve 47, 72\u201380 (2013).","journal-title":"Muscle Nerve"},{"key":"BFsrep40461_CR32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10557-013-6445-1","volume":"27","author":"R Baetta","year":"2013","unstructured":"Baetta, R. et al. Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol. Cardiovasc. Drugs Ther. 27, 211\u2013219 (2013).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"BFsrep40461_CR33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00008480-200404000-00017","volume":"16","author":"TJ Coco","year":"2004","unstructured":"Coco, T. J. & Klasner, A. E. Drug-induced rhabdomyolysis. Curr. Opin. Pediatr. 16, 206\u2013210 (2004).","journal-title":"Curr. Opin. Pediatr."},{"key":"BFsrep40461_CR34","first-page":"457","volume":"70","author":"D Manor","year":"1989","unstructured":"Manor, D. & Sadeh, M. Muscle fibre necrosis induced by intramuscular injection of drugs. Br. J. Exp. Pathol. 70, 457\u2013462 (1989).","journal-title":"Br. J. Exp. Pathol."},{"key":"BFsrep40461_CR35","doi-asserted-by":"crossref","first-page":"e32785","DOI":"10.1371\/journal.pone.0032785","volume":"7","author":"M Pasarin","year":"2012","unstructured":"Pasarin, M. et al. Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PLoS One 7, e32785 (2012).","journal-title":"PLoS One"},{"key":"BFsrep40461_CR36","first-page":"738","volume":"143","author":"A Couvelard","year":"1993","unstructured":"Couvelard, A. et al. Expression of cell-cell and cell-matrix adhesion proteins by sinusoidal endothelial cells in the normal and cirrhotic human liver. Am. J. Pathol. 143, 738\u2013752 (1993).","journal-title":"Am. J. Pathol."},{"key":"BFsrep40461_CR37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrgastro.2015.78","volume":"12","author":"J Bosch","year":"2015","unstructured":"Bosch, J. & Forns, X. Statins and liver disease: from concern to \u2018wonder\u2019 drugs? Nat. Rev. Gastroenterol. Hepatol. 12, 320\u2013321 (2015).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"BFsrep40461_CR38","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jhep.2015.07.009","volume":"63","author":"JC Hsiang","year":"2015","unstructured":"Hsiang, J. C. et al. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity score landmark analysis. J. Hepatol. 63, 1190\u20131197 (2015).","journal-title":"J. Hepatol."},{"key":"BFsrep40461_CR39","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2015.07.006","volume":"63","author":"YH Yang","year":"2015","unstructured":"Yang, Y. H. et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J. Hepatol. 63, 1111\u20131117 (2015).","journal-title":"J. Hepatol."},{"key":"BFsrep40461_CR40","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","volume":"63","author":"P Dongiovanni","year":"2015","unstructured":"Dongiovanni, P. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J. Hepatol. 63, 705\u2013712 (2015).","journal-title":"J. Hepatol."},{"key":"BFsrep40461_CR41","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","volume":"150","author":"A Mohanty","year":"2015","unstructured":"Mohanty, A. et al. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology 150, 430\u2013440 (2015).","journal-title":"Gastroenterology"},{"key":"BFsrep40461_CR42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep.27835","volume":"62","author":"AA Butt","year":"2015","unstructured":"Butt, A. A. et al. Effect of addition of statins to antiviral therapy in hepatitis C virus\u2013infected persons: results from ERCHIVES. Hepatology 62, 365\u2013374 (2015).","journal-title":"Hepatology"},{"key":"BFsrep40461_CR43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/liv.12472","volume":"35","author":"S Rodr\u00edguez","year":"2015","unstructured":"Rodr\u00edguez, S. et al. The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats. Liver Int. 35, 326\u2013334 (2015).","journal-title":"Liver Int."},{"key":"BFsrep40461_CR44","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0168-8278(97)80473-4","volume":"26","author":"F Oberti","year":"1997","unstructured":"Oberti, F. et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J. Hepatol. 26, 1363\u20131371 (1997).","journal-title":"J. Hepatol."},{"key":"BFsrep40461_CR45","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1440-1746.2009.06159.x","volume":"25","author":"HC Huang","year":"2010","unstructured":"Huang, H. C. et al. Simvastatin effects on portal-systemic collaterals of portal hypertensive rats. J. Gastroenterol. Hepatol. 25, 1401\u20131409 (2010).","journal-title":"J. Gastroenterol. Hepatol"},{"key":"BFsrep40461_CR46","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.26127","volume":"57","author":"V La Mura","year":"2013","unstructured":"La Mura, V. et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology 57, 1172\u20131181 (2013).","journal-title":"Hepatology"},{"key":"BFsrep40461_CR47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","volume":"64","author":"P Gazzerro","year":"2012","unstructured":"Gazzerro, P. et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev. 64, 102\u2013146 (2012).","journal-title":"Pharmacol. Rev."},{"key":"BFsrep40461_CR48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0005-2760(97)00182-3","volume":"1389","author":"JD Bergstrom","year":"1998","unstructured":"Bergstrom, J. D. et al. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA-reductase: a comparison of atorvastatin and simvastatin. Biochim. Biophys. Acta 1389, 213\u2013221 (1998).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFsrep40461_CR49","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/j.1552-4604.1992.tb03818.x","volume":"32","author":"PJ Pentikainen","year":"1992","unstructured":"Pentikainen, P. J. et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J. Clin. Pharmacol. 32, 136\u2013140 (1992).","journal-title":"J. Clin. Pharmacol"},{"key":"BFsrep40461_CR50","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1358\/mf.2003.25.6.769652","volume":"25","author":"MJ Garcia","year":"2003","unstructured":"Garcia, M. J. et al. Clinical pharmacokinetics of statins. Methods Find. Exp. Clin. Pharmacol. 25, 457\u2013481 (2003).","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"BFsrep40461_CR51","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jbt.21485","volume":"27","author":"N Abdoli","year":"2013","unstructured":"Abdoli, N. et al. Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes. J. Biochem. Mol. Toxicol. 27, 287\u2013294 (2013).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"BFsrep40461_CR52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-0031-1278256","volume":"16","author":"M Fujita","year":"2007","unstructured":"Fujita, M. et al. Dose-dependency in pleiotropic effects of atorvastatin. Int. J. Angiol. 16, 89\u201391 (2007).","journal-title":"Int. J. Angiol"},{"key":"BFsrep40461_CR53","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller, R. & Brenner, D. A. Liver fibrosis. J. Clin. Invest. 115, 209\u2013218 (2005).","journal-title":"J. Clin. Invest."},{"key":"BFsrep40461_CR54","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1053\/j.gastro.2011.12.017","volume":"142","author":"GH Xie","year":"2012","unstructured":"Xie, G. H. et al. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology 142, 918\u2013U392 (2012).","journal-title":"Gastroenterology"},{"key":"BFsrep40461_CR55","doi-asserted-by":"crossref","first-page":"24266","DOI":"10.1074\/jbc.273.37.24266","volume":"273","author":"U Laufs","year":"1998","unstructured":"Laufs, U. & Liao, J. K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rho GTPase. J. Biol. Chem. 273, 24266\u201324271 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFsrep40461_CR56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0168-8278(95)80345-9","volume":"23","author":"PL Beck","year":"1995","unstructured":"Beck, P. L. & Lee, S. S. Vitamin-K-1 improves survival in bile-duct-ligated rats with cirrhosis. J. Hepatol. 23, 235 (1995).","journal-title":"J. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep40461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep40461","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep40461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T19:45:21Z","timestamp":1671824721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep40461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3,7]]}},"alternative-id":["BFsrep40461"],"URL":"https:\/\/doi.org\/10.1038\/srep40461","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727203176.793545266","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,13]]},"assertion":[{"value":"13 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2017","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The version of this Article previously published incorrectly listed M.T., and not M.T.-A., in the Author Contributions section. This has now been corrected in the PDF and HTML versions of the Article as well as the Supplementary Information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40461"}}